A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple Myeloma
A Phase 1 First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 232 in Adult Subjects With Advanced Solid Tumors or Multiple Myeloma
Sponsor: Kartos Therapeutics, Inc.
This PHASE1 trial investigates Advanced Malignancy and Advanced Solid Tumors and is currently completed. Kartos Therapeutics, Inc. leads this study, which shows 10 recorded versions since 2012 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE1
▶ Show 5 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1
-
Oct 2017 — Jun 2018 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2017 — Oct 2017 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — May 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Kartos Therapeutics, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .